Wall Street Zen Upgrades Structure Therapeutics to Hold Rating

Wall Street Zen has upgraded its rating on Structure Therapeutics (NASDAQ: GPCR) from “sell” to “hold,” according to a report released on Saturday. This change in rating reflects a shift in analysts’ perspectives on the stock, which has seen varied assessments from multiple research firms in recent months.

Recent Analyst Ratings and Target Prices

In a separate report issued on November 28, HC Wainwright reaffirmed a “buy” rating for Structure Therapeutics, setting a target price of $60.00 per share. Meanwhile, Morgan Stanley increased its price target for the stock from $120.00 to $125.00, assigning it an “overweight” rating. This indicates a positive outlook for the company amidst fluctuating ratings.

On the other hand, Stifel Nicolaus raised its price objective from $50.00 to $90.00, also giving the company a “buy” rating. Contrasting these positive assessments, Zacks Research downgraded Structure Therapeutics from a “hold” rating to a “strong sell” on October 17, 2023. Additionally, Lifesci Capital upgraded the stock to a “strong buy” on September 8, 2023, showcasing a diverse range of opinions among analysts.

Currently, one analyst has assigned a “strong buy” rating, eleven have issued a “buy” rating, and two have opted for a “sell” assessment. Data from MarketBeat indicates that Structure Therapeutics holds an average rating of “moderate buy” with a target price of $95.78.

Financial Performance and Expectations

Structure Therapeutics recently reported its quarterly earnings on November 6, 2023. The company posted an earnings per share (EPS) of ($0.37), falling short of the consensus estimate of ($0.36) by $0.01. Analysts anticipate that the company will report an EPS of ($0.82) for the current fiscal year, indicating challenges ahead despite the mixed ratings.

Institutional investors have shown interest in Structure Therapeutics, with several hedge funds adjusting their positions. The State of Wyoming acquired a new stake in the company during the second quarter, valued at approximately $28,000. EverSource Wealth Advisors LLC increased its stake by an impressive 530.0% in the third quarter, owning 1,071 shares valued at $30,000 after acquiring an additional 901 shares.

Additionally, National Bank of Canada FI raised its position by 1,448.2% in the first quarter, now holding 2,957 shares worth $51,000 after purchasing 2,766 additional shares. Assetmark Inc. and PNC Financial Services Group Inc. also boosted their stakes by 39.9% and 29.1%, respectively, reflecting strong institutional interest in the company. Currently, approximately 91.78% of the stock is owned by hedge funds and institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing innovative oral therapeutics to address various chronic diseases with unmet medical needs. The company’s leading product candidate, GSBR-1290, is an oral small-molecule agonist targeting the glucagon-like peptide-1 receptor, a validated target for treating type-2 diabetes mellitus and obesity.

As the company navigates its financial landscape, analysts and investors will be closely monitoring its upcoming performance and the impact of recent upgrades on its stock trajectory.